• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Barg Steven was granted 1,427 shares (SEC Form 4)

    6/4/25 4:38:36 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $CRL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Barg Steven

    (Last) (First) (Middle)
    C/O CHARLES RIVER LABORATORIES
    251 BALLARDVALE STREET

    (Street)
    WILMINGTON MA 01887

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/02/2025 A 481(1) A $135.04 481 D
    Common Stock 06/02/2025 A 946(2) A $135.04 1,427 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options (Right to Buy) $135.04 06/02/2025 A 2,082(3) 06/02/2026 06/02/2035 Common Stock 2,082 $135.04 2,082 D
    Explanation of Responses:
    1. The grant was made in lieu of director service fees for the term commencing May 20, 2025. The restricted stock units vest upon the earlier of 6/2/2026, or the business day prior to the Company's next annual meeting of shareholders.
    2. The unvested restricted stock units vest upon the earlier of 6/2/2026 or the business day prior to the Company's next annual meeting of shareholders.
    3. The stock options become exercisable upon the earlier of 6/2/2026 or the business day prior to the Company's next annual meeting of shareholders.
    /s/ Steven Barg 06/04/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CRL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRL

    DatePrice TargetRatingAnalyst
    5/23/2025$182.00Neutral → Buy
    Redburn Atlantic
    5/14/2025$179.00Hold → Buy
    TD Cowen
    5/8/2025$170.00In-line → Outperform
    Evercore ISI
    3/21/2025$190.00 → $170.00Buy → Neutral
    Goldman
    3/4/2025$155.00 → $175.00Sell → Neutral
    Citigroup
    3/3/2025$188.00Sell → Neutral
    Redburn Atlantic
    1/22/2025Outperform → Mkt Perform
    William Blair
    1/17/2025$250.00 → $185.00Buy → Neutral
    UBS
    More analyst ratings

    $CRL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Mintz Mark claimed ownership of 6,350 shares (SEC Form 3)

      3 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      6/10/25 4:22:44 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • EVP, Corp Strategy & Develop Laplume Joseph W gifted 385 shares, decreasing direct ownership by 1% to 25,316 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      6/9/25 4:21:38 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Ceesay Abraham was granted 946 shares (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      6/4/25 4:45:04 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Charles River upgraded by Redburn Atlantic with a new price target

      Redburn Atlantic upgraded Charles River from Neutral to Buy and set a new price target of $182.00

      5/23/25 8:13:14 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River upgraded by TD Cowen with a new price target

      TD Cowen upgraded Charles River from Hold to Buy and set a new price target of $179.00

      5/14/25 8:48:54 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Charles River from In-line to Outperform and set a new price target of $170.00

      5/8/25 8:24:10 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care